Anixa Biosciences Inc (NASDAQ:ANIX) Receives Average Recommendation of “Hold” from Analysts

Anixa Biosciences Inc (NASDAQ:ANIX) has received a consensus recommendation of “Hold” from the five brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $9.00.

ANIX has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Friday, December 12th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Finally, Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, January 17th.

Insider Buying and Selling at Anixa Biosciences

In other news, Director Arnold M. Baskies purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, January 28th. The stock was purchased at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the acquisition, the director owned 135,000 shares of the company’s stock, valued at approximately $410,400. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 25.30% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Westside Investment Management Inc. lifted its holdings in shares of Anixa Biosciences by 25.7% in the 4th quarter. Westside Investment Management Inc. now owns 44,000 shares of the company’s stock worth $137,000 after buying an additional 9,000 shares during the period. CIBC Bancorp USA Inc. bought a new stake in shares of Anixa Biosciences in the third quarter valued at about $51,000. Susquehanna International Group LLP lifted its stake in Anixa Biosciences by 378.4% in the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after acquiring an additional 63,584 shares during the period. Prosperity Wealth Management Inc. lifted its stake in Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after acquiring an additional 5,300 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares in the last quarter. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Trading Up 2.3%

Shares of NASDAQ:ANIX opened at $3.10 on Friday. Anixa Biosciences has a 12 month low of $2.33 and a 12 month high of $5.46. The company has a market capitalization of $103.48 million, a price-to-earnings ratio of -8.86 and a beta of 0.49. The firm’s 50-day moving average is $3.67 and its 200 day moving average is $3.59.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Monday, January 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). As a group, equities analysts forecast that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.